NIH, industry and non-profits join forces to speed validation of disease targets
Goal is to develop new treatments earlier, beginning with Alzheimer’s, type 2 diabetes, and autoimmune disorders
The National Institutes of Health, 10 biopharmaceutical companies and several nonprofit organizations today launched an unprecedented partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development. The Accelerating Medicines Partnership (AMP) aims to distinguish biological targets of disease most likely to respond to new therapies and characterize biological indicators of disease, known as biomarkers.
This page was last updated on Friday, January 21, 2022